See more : Tripadvisor, Inc. (TRIP) Income Statement Analysis – Financial Results
Complete financial analysis of BridgeBio Pharma, Inc. (BBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BridgeBio Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pixie Dust Technologies, Inc. (PXDT) Income Statement Analysis – Financial Results
- Reliance Industrial Infrastructure Limited (RIIL.NS) Income Statement Analysis – Financial Results
- Epigral Limited (EPIGRAL.BO) Income Statement Analysis – Financial Results
- Pacific Century Premium Developments Limited (0432.HK) Income Statement Analysis – Financial Results
- Rockwool A/S (ROCK-B.CO) Income Statement Analysis – Financial Results
BridgeBio Pharma, Inc. (BBIO)
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.30M | 77.65M | 69.72M | 8.25M | 40.56M | 0.00 | 0.00 |
| Cost of Revenue | 2.45M | 3.43M | 3.11M | 3.09M | 2.50M | 0.00 | 260.00K |
| Gross Profit | 6.86M | 74.21M | 66.60M | 5.16M | 38.06M | 0.00 | -260.00K |
| Gross Profit Ratio | 73.71% | 95.58% | 95.53% | 62.57% | 93.84% | 0.00% | 0.00% |
| Research & Development | 455.71M | 402.90M | 454.14M | 337.05M | 209.95M | 140.07M | 30.56M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 145.68M | 94.35M | 43.59M | 13.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.59M | 143.19M | 192.21M | 145.68M | 94.35M | 43.59M | 13.30M |
| Other Expenses | 7.93M | 100.45M | 35.82M | 1.63M | -1.21M | -1.29M | 0.00 |
| Operating Expenses | 614.23M | 546.09M | 646.35M | 482.73M | 304.30M | 183.66M | 43.86M |
| Cost & Expenses | 616.67M | 546.09M | 646.35M | 482.73M | 306.80M | 183.66M | 43.86M |
| Interest Income | 18.04M | 7.54M | 1.13M | 4.02M | 8.92M | 2.00M | 39.00K |
| Interest Expense | 81.29M | 80.44M | 46.78M | 36.66M | 8.77M | 2.55M | 13.00K |
| Depreciation & Amortization | 6.49M | 6.77M | 5.84M | 3.09M | 859.00K | 245.00K | 260.00K |
| EBITDA | -565.47M | -397.44M | -533.83M | -465.75M | -279.82M | -183.42M | -43.56M |
| EBITDA Ratio | -6,078.34% | -455.49% | -774.11% | -5,683.51% | -688.87% | 0.00% | 0.00% |
| Operating Income | -607.37M | -471.87M | -579.75M | -474.48M | -266.24M | -183.66M | -43.86M |
| Operating Income Ratio | -6,528.75% | -607.71% | -831.58% | -5,751.99% | -656.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | -45.88M | 27.55M | -9.82M | -31.01M | -22.35M | 14.21M | 26.00K |
| Income Before Tax | -653.25M | -484.65M | -586.45M | -505.49M | -288.59M | -169.45M | -43.83M |
| Income Before Tax Ratio | -7,021.94% | -624.17% | -841.20% | -6,127.87% | -711.50% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.31M | 52.84M | -21.56M | -28.15M | 16.76M | -13.49M |
| Net Income | -643.20M | -493.96M | -639.30M | -483.93M | -260.44M | -130.75M | -30.57M |
| Net Income Ratio | -6,913.92% | -636.16% | -917.00% | -5,866.47% | -642.10% | 0.00% | 0.00% |
| EPS | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| EPS Diluted | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| Weighted Avg Shares Out | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
| Weighted Avg Shares Out (Dil) | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
3 Top Stocks That Could Still Rocket Higher in 2024
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
Source: https://incomestatements.info
Category: Stock Reports